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Abstract
Background: Endometrial adenocarcinoma usually occurs after menopause, but in 2%–14% of cases, it occurs in young patients (less 
than 40 years of age) who are eager to preserve their fertility. Its treatment includes hysterectomy, bilateral salpingo-oophorectomy and 
pelvic lymphadenectomy, and, in some cases, radiation therapy.
Aim: To describe a case of endometrial adenocarcinoma occurring in a young woman and to undertake a literature review of risk   factors 
and therapeutic options proposed for young women wishing to preserve their fertility.
Case: We report a case of endometrial cancer in a 27-year-old woman treated for resistant menorrhagia and cared for in our department 
as well as in the Salah Azaiez Institute.
Conclusion: Endometrial adenocarcinoma rarely occurs in young women. In such cases, other therapeutic options can be proposed: 
progesterone therapy and LH-RH (Luteinzing-Hormone-Releasing-Hormone) agonists therapy in order to preserve fertility in younger 
patients.
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Endometrial  adenocarcinoma  usually  occurs  after 
menopause. However, in 2%–14% of cases, it occurs 
in young women (less than 40), most of whom wish 
to  preserve  their  fertility.1–4  In  a  literature  review, 
  Vaccarello et al5 observed that the majority of cases of 
endometrial adenocarcinoma in young women were of 
endometrioid type, well differentiated (Grade 1) and 
at early stages with a superficial invasion (Stage I). 
Therefore, these carcinomas had a good prognosis 
(survival rate at five years: .93%).
The  classic  treatment  consists  of  a  total 
  hysterectomy and/or a salpingo-oophorectomy with 
or  without  a  pelvic  or  aortic  lymphadenectomy. 
However, there is a therapeutic alternative for young 
women wishing to become pregnant in the future. 
In  fact,  a  certain  number  of  publications  report 
attempts to find a conservative treatment for young 
women  carrying  endometrial  adenocarcinoma  at 
Stage IA, Grade 1.3,6–14 These kinds of therapies are 
not   standard management and should not be recom-
mended routinely. Patients must be informed of the 
oncological risks (failure, progression of the disease, 
ovarian metastasis, etc.).15
We report the case of a 27-year-old patient with 
an endometrial cancer diagnosed at Stage Ic grade 1 
according to the FIGO (International Federation of 
Gynecology  and  Obstetrics)  2000  classification  of 
endometrial cancer.16
Observation
A  27-year-old  patient  who  was  nulliparous  and 
overweight (body mass index = 28) was referred to us 
by her regular doctor for menorrhagia that was resistant 
to progestogens. A verbal examination revealed that 
the patient required blood transfusion for treating her 
menorrhagia, which had continued for a period of 
about five years. The physical examination revealed 
little. A  trans-vaginal  ultrasound  led  us  to  suspect 
an endometrial hypertrophy and the presence of an 
endometrial  polyp. A  hysteroscopy  was  scheduled 
but we lost trace of the patient. She presented five 
months later for metrorrhagia associated with fetid 
hydrorrhea.  A  hysteroscopy  revealed  an  area  of 
endometrial polyposis reaching the uterine isthmus. 
A  haemostatic  uterine  curettage  was  performed 
successfully. The histological examination confirmed 
the presence of an endometrial adenocarcinoma of 
endometrioid type that was well differentiated and 
Grade  1.    During  the  extent’s  assessment,  an  MRI 
scan revealed a focal myometrial invasion of more 
than  50%  without  extension  to  the  serous  mem-
brane and infracentimetric bilateral hypogastric and 
inguinal lymph nodes. The other abdominal organs 
were lesion-free.
The patient underwent a total hysterectomy with 
bilateral salpingo-oophorectomy and pelvic lymph-
adenectomy.  The  pathological  exam  showed  an 
adenocarcinoma of endometrioid type (Stage IC and 
Grade 1 according to the FIGO 2000 classification of 
endometrial cancer) that had invaded the whole uterine 
cavity,  and  a  focal  fundic  myometrial  infiltration 
reaching the outer third of the wall without reaching 
the serosa; the cervical canal, lymph nodes, fallopian 
tubes  and  ovaries  were  lesion-free.  The  surgery 
was followed by vaginal curietherapy and external 
radiotherapy. The follow-up, three years after the end 
of radiotherapy, was uneventful.
Discussion
Most  endometrial  adenocarcinomas  occur  after 
menopause. However, 20%–25% of them are diagnosed 
before  the  menopause  and  2%–14%  occur  among 
younger women (less than 40).1–4 The most reported 
risk  factors  of  endometrial  cancer  are  anovular 
cycles  associated  with  polycystic  ovarian  syn-
drome  (PCD),  hypertension,  diabetes,  obesity,  the 
sole  use  of  estrogens  and  the  use  of  tamoxifen.17 
Several authors4,18–23 have tried to individualize the 
risk factors of endometrial adenocarcinoma related 
specifically  to  women  under  40.  Younger  patients 
with endometrial carcinoma tend to have a history 
of  estrogen  use  or  hormone-related  disorders  such 
ovarian dysfunction, chronic anovulation, infertility, 
obesity and PCO (odds ratio: 3.1; 95% confidence 
interval: 1.1–7.3).23 Our patient had problems with 
excess weight and infertility. An association between 
PCO and endometrial cancer in younger women is 
consistent with the hypothesis that the stimulatory 
effect of estrogen on the endometrium, if unopposed 
by progesterone, can induce endometrial carcinogen-
esis. PCO is also associated with hyperinsulinaemia 
and insulin resistance (insulin and IGF-I stimulate 
endometrial  carcinoma  cells  in  vitro),  and  with 
hyperandrogenism by enhancing aromatase activity. 
These endocrine factors may underpin the association 
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Endometrial  carcinomas  associated  with  PCO  do 
not seem to have a better prognosis than those with 
normal ovaries.23,24
It is estimated that 2%–5% of endometrial cancer 
may  be  attributed  to  an  inherited  predisposition  to 
cancer.  Lynch  syndrome  (hereditary  nonpolyposis 
  colorectal cancer syndrome) accounts for the majority 
of  inherited  endometrial  cancers  and  for  6%  of  all 
endometrial cancers, especially in young patients.25–27 
Germline  mutations  in  one  of  the  DNA  mismatch 
repair  genes  hMLH1,  hMLH2,  hMSH6  or  hPMS2 
have been identified in patients with Lynch syndrome. 
These mutations are inherited in an autosomal domi-
nant fashion. Individuals with Lynch syndrome inherit 
one nonfunctional allele; when subsequent loss of the 
corresponding allele occurs, genetic DNA repairs are 
defective in target tissues such as the endometrium.3,25
The most important prognosis factors of endometrial 
adenocarcinomas  are  the  histological  grade,  the 
cancer  stage  and  the  myometrial  invasion.  This 
gives rise to the question whether there are specific 
prognosis factors in young women with endometrial 
cancer. Several studies19,20,21,28 have not observed a 
difference  in  the  frequency  of  Stage  I  carcinomas 
(approximately 70% in both groups). According to 
the studies of Evans-Metcalf et al19 and Fahri et al22 
it seems that the frequency of Grade 1 tumors was 
higher  in  young  women,  reaching  90%.  Another 
study21 reports a myometrial invasion rate that was 
more than 50% lower in young women (24% vs. 49% 
in older women). Two studies19,28 have shown that 
the association of endometrial adenocarcinoma with 
ovarian one seems to be more frequent in younger 
women than older ones (29% vs. 4.6%).
Surgery is the classic treatment for endometrial 
cancer. It consists of total hysterectomy and bilateral 
salpingo-oophorectomy,  with  a  pelvic  and  aortic 
lymphadenectomy  if  required.  Curietherapy  and 
radiotherapy are indicated when there is a high risk of 
recurrence. The young women affected by endometrial 
cancer  are  often  nulliparas  with  a  past  history  of 
infertility and thus are very anxious to preserve their 
fertility. This constitutes a dilemma for the patients as 
well as their physicians.
Fortunately, 70% of the endometrial adenocarcino-
mas in young women are at Stage I and 90% of them 
are Grade 1 carcinomas, which have a good prognosis 
and offer other therapeutic possibilities instead of the 
standard radical treatment.
Some authors29,30 have proposed repeated endome-
trial curettages or hysteroscopic resection of cancer-
ized polyps; however, most conservative treatments 
are inspired by the hormone-dependence of endome-
trial adenocarcinomas. In fact, a large proportion of 
endometrial cancers express estrogen and progestogen 
receptors.31 Both estrogen and progesterone exert their 
effects through intra-nuclear receptors, estrogen recep-
tors (ER; α and β) and progesterone receptors (PR; A 
and B).15 The expression of ER and PR is generally 
considered to be coordinated because transcription of 
the PR gene is induced by estrogen and inhibited by 
progesterone in the great majority of estrogen respon-
sive cells.15 During the secretory phase when circu-
lating  concentrations  of  progesterone  are  maximal, 
activation of PR results in reduced proliferative and 
increased cellular differentiation.32 It has been demon-
strated that in endometrial cancer from clinical Stages 
III–IV, ER and PR concentrations are lower than those 
in Stage I endometrial cancer. Also, in Stage I samples, 
higher concentrations of receptors were measured in 
the well and moderately differentiated samples.32 The 
detection of PR in endometrial adenocarcinomas is 
associated with a better disease-free survival, while 
the loss of expression of PR isoforms may result in 
more aggressive biological characteristics in human 
endometrioid endometrial carcinomas that can play an 
important role in the prognosis and/or recurrence in 
these  patients.15 Endometrial carcinomas, especially 
of  the  well-differentiated  endometrioid  type,  often 
express PR and their growth is suppressed by proges-
tins. In general, the effect of progestins is considered 
to be mediated through PR, because the response rate 
to  progestins  in  PR-positive  carcinoma  was  higher 
(70%) compared with PR-negative tumors (16%).33,34 
It has recently been shown that they express Gn-RH 
(Gonadotropin-Releasing  Hormone)  receptors,35 
which  implies  that  progestins  and  Gn-RH  agonists 
are the most useful medicines in the framework of 
conservative treatment of endometrial cancer (Stage I, 
Grade 1).
The progestogens have been used for a long time 
for  palliative  treatment  in  advanced  endometrial 
cancers,  with  a  response  rate  ranging  from  20%  to 
40% (this limited response likely to be related to a 
lack of receptors in the tumor cells of advanced stage 
endometrial carcinoma in younger patients
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treatment  of  endometrial  adenocarcinoma  in  young 
women dates back to 1968 in a study by Kempson 
and Pokorny.37 Since then, several short series (with 
an average   follow-up of 32 months) have shown high 
response rates with the possibility of future full-term 
pregnancies.1,6–8,22,38,39 The response rate varies from 57 
to 75% and the recurrence rate ranges from 11% to 50%.1 
These rates seem to be quite encouraging.   However, 
we should not ignore the side effects of progestogens 
given at high doses,   notably embolism associated with 
deep-vein    thrombosis  (5%–10%),40,41  disturbance  of 
the lipid metabolism, the risk of   atherogenesis, reduced 
sexual drive (libido) and mood disorders.
The  literature  analysis  shows  no  established 
consensus regarding:
-	 the choice of the progestogen to use, even though 
medroxyprogesterone  acetate  and  megestrol 
acetate seem to be the most used;
-	 the  dose  of  progestogen  to  prescribe,  even 
though most studies report a dose of 600 mg of 
medroxyprogesterone  acetate  per  day,  taken  in 
200 mg amounts three times a day;42
-	 the  duration  of  the  treatment,  which  varies 
according to the authors from 3 to 9 months.6,7 
A duration of six months seems to be an acceptable 
compromise.2
The Gn-RH agonists have been used principally 
in  the  management  of  metastatic  and  recurrent 
endometrial cancers after unsuccessful surgery and/
or  radiotherapy.  Remission  rates  up  to  57%  have 
been reported.31,36,43 As far as the patients younger 
than 40 are concerned, only nine cases have been 
reported.1,44  These  nine  patients  have  been  treated 
for a period of 3 to 6 months, culminating in normal 
endometrial biopsies. Five patients became pregnant, 
and four carried their babies to term. The principal 
side effect of the Gn-RH agonist is bone demineral-
ization, especially when the treatment exceeds 3 to 
4  months.45  Other  side-effects  of  Gn-RH  agonists 
such as vaginal dryness, hot flushes, reduced sexual 
interest, insomnia, headache, depression, nausea and 
vomiting are intolerable in about 10% of patients.1 
Add-back therapy with tibolone has been proposed 
in order to limit this demineralization. However, this 
approach should be carried out carefully because of 
the absence of data concerning the effects of tibolone 
on neoplastic cells, even if it is admitted that it does 
not result in endometrial proliferation.46,47 The results 
obtained with Gn-RH agonists seem encouraging, yet 
literature on the subject remains scarce.
In  2002,  Montz  et  al9  have  published  a  series 
about  12  women  with  an  endometrial  cancer 
(Stage  I,  Grade  1)  treated  with  a  progestogen 
intra-uterine device for one year with normalization 
of the endometrium in six of them after a period of 
six months. As this is a series of insufficient size, we 
cannot draw any conclusions, even though the results 
seem to be convincing. More recently, other cases 
have been reported48–50 with results that are somewhat 
convincing.
Aromatase  inhibitors  such  as  anastrozole 
(Arimidex™,  manufactured  by  Astra  Zeneca)  are 
able to effectively stop the peripheral conversion of 
androgens to estrogens. Such a conversion is the major 
source of estrogens in obese patients with endometrial 
cancer.  Anastrozole  seems  to  be  able  to  reduce 
aromatase activity by 96%, thus dropping estradiol 
and estrone levels by 80%. To our knowledge, no study 
dealing with the use of only aromatase inhibitors in the 
early stage of   endometrial   adenocarcinoma has been 
published to date.51 However, Burnett et al52 reported 
the successful use of a combination of   Anastrozole 
(an  aromatase    inhibitor)  and    medroxyprogesterone 
acetate (an anti-estrogen) in the treatment of Stage IA   
Grade  1  endometrial  carcinoma  in  two  obese  pre-
menopausal women (19 and 39 years old). Such an 
association should reduce the duration of treatment, 
so women will be more able to conceive, particularly 
if they are approaching the upper ages of reproductive 
potential. Aromatase inhibitors have been also used 
in patients having an endometrial adenocarcinoma at 
an advanced stage.1
Despite the disappearance of endometrial lesions 
in  57%  to  75%  of  the  cases  after  conservative 
treatment, the recurrence rate after stopping the treat-
ment is about 40% for a follow-up ranging between 7 
and 22 months42 and about 67% after a follow-up of 
30 months.53 This relatively high rate can be explained 
by an initial mis-diagnosis of the cancer stage, a poor 
diagnostic  sensitivity  during  the  follow-up  or  by 
progressive resistance of the tumor to the treatment,2 
or else by the reappearance of the same factors that 
induced endometrial cancer in the first place upon 
discontinuation of progestogen therapy, e.g. a defect 
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genes.54
According to the international literature, it appears 
that  the  most  important  factor  for  conservative 
treatment is selecting the “ideal patient”.55 That is:
-	 a well-differentiated endometrial carcinoma that 
does not deeply invade the myometrium,
-	 absence of suspicious pelvic or pre-aortic nodes.
-	 absence of synchronous ovarian tumors,
-	 no contraindications for medical treatment,
-	 the patient understands and accepts that this is not 
a standard treatment,
-	 the patient should show her desire to complete the 
follow-up protocol.
Optimized evaluation of the FIGO stage in these 
young patients, whom we do not wish to operate on, 
uses a combination of some or all of hysteroscopy, 
curettage,  a  pelvic  trans-vaginal  ultrasound  scan, 
MRI  scanning  and  serum  CA125  measurements 
(extra-uterine  invasion  is  indicated  if  the  CA125 
concentration  is  over  35  UI/mL)  even  though  the 
latter is not specific enough, as it can also be caused 
by  endometriosis,  fibroids,  liver  disease  etc.2,56–59 
Preoperative  assessment  of  the  histological  grade, 
using  endometrial  biopsy  or  curettage,  has  only  a 
moderate  ability  to  predict  final  pathology. Tumor 
grade at diagnosis matches the tumor grade determined 
after hysteroscopy in 58% of patients diagnosed via 
endometrial biopsy (Pipelle) and 77% of the patients 
diagnosed  via  dilatation  and  curettage  (D  &  C).60 
Hysteroscopy is thus essential; it allows the lesion 
and biopsy to be seen directly. However, the risk of 
spreading cancer cells is not   theoretically zero.61 The 
depth of myometrial invasion can be estimated with 
surrogate staging techniques, such as those using ultra-
sound and MRI scanning. However, MRI has limited 
sensitivity to differentiate between stage IA and stage 
IB disease.62 The accuracy of T2-weighted images 
in the determination of myometrial invasion varies 
between 68% and 82%.1,35,63 The use of a dynamic 
study  after  administration  of  intravenous  contrast 
increases  the  accuracy  of    myometrial  invasion  to 
85%–91%.2,35,63 An ultrasound is necessary to view 
the appearance, the thickness of the endometrium, 
the depth of endometrial invasion (with a sensitivity 
of  88%)  and  the  ovaries.64  Synchronous  ovarian 
malignancies have been observed in up to 25% of 
the cases of endometrial cancer in younger women 
compared with only 2% in older patients. This high 
incidence  of  coexisting  ovarian  malignancies  and 
the  young  age  at  diagnosis  suggest  an  increased 
susceptibility of the reproductive organs to carcinogenic 
transformation.12,60,65–69  A  literature  review  indicates   
that surgical exploration by the means of laparoscopy 
could be helpful to verify the absence of suspicious 
macroscopic lesions on the ovaries; furthermore, a lap-
aroscopy allows us to make a macroscopic assessment 
of the peritoneal cavity (peritoneal cytology) and to 
ensure  temporary  occlusion  by  laparoscopy  of  the 
tubes where they emerge, thus   avoiding the risk of 
cancer cells migrating to the peritoneal cavity dur-
ing hysteroscopy. Laparoscopy also makes a lymph-
adenectomy possible, thus increasing the accuracy of 
the assessment of the cancer’s extent.2,61,70 Cervical 
involvement can be assessed by the means of MRI 
scanning.  Indeed,  the  accuracy,  sensitivity  and 
specificity of MRI scans were 80%, 33% and 100% 
(when compared to surgical staging of endometrial 
carcinoma). The use of a dynamic study after admin-
istration of intravenous contrast is helpful in the cases 
where the junctional zone is not clearly visualized.71 
Hysteroscopy seems to be more reliable than MRI and 
transvaginal  ultrasound  scan  in  excluding  cervical 
canal involvement, while MRI is the most reliable 
technique for predicting cervical involvement (posi-
tive predictive value of hysteroscopy: 58% vs. 71% 
for MRI; specificity 88% vs. 95%).72,73 According to 
Almog,74,75 fractional D & C appears to be the best 
method to predict cervical involvement adequately.
The  same  diagnostic  arsenal  (i.e.  hysteroscopy, 
endometrial curettage, endo-vaginal ultrasound scan, 
MRI) is used in post-therapeutic follow-up. However, 
there  is  no  consensus  regarding  its  modalities 
(periodicity:  12  to  24  weeks;  hysteroscopy  with 
guided biopsy or D & C).55,61
The  principal  aim  of  conservative  treatment  in 
endometrial adenocarcinoma is the preservation of the 
patients’  fertility  [Table  1].  Following  regression  of 
endometrial cancer as documented by D & C, women 
without a history of infertility can immediately try to 
conceive  naturally;2,76  the  spontaneous  pregnancy 
rate in such situation is about 25%.2,61 After a period 
of  three  months  with  no  pregnancy,  a  preliminary 
infertility appraisal is appropriate. In the case of a his-
tory of infertility, it seems logical to proceed to assisted 
endometrial carcinoma in younger patients
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infertile patients aged 35 and older. Even if the FSH 
(Follicle stimulating hormone) increases the estrogen 
rate because of ovarian stimulation, this increase is of 
short duration and is not significant enough to lead to 
tumor development. In addition, a correlation between 
induction of ovulation and the emergence of an endo-
metrial cancer has not been proved.76 Although the delay 
between the end of treatment and attempts to achieve 
pregnancy has not been established, it seems logical to 
implement ART as soon as possible.77
After  bringing  a  pregnancy  to  term,  a  radical 
treatment  should  be  proposed  and  discussed  with 
the patient.2 If radical treatment is refused or if other 
pregnancies are desired, there is no consensus on the 
appropriate  management  of  the  woman’s  condition. 
However, a continuing treatment by estro-progestogen 
contraception  or  by  Depo-Provera™  (150  mg  of 
medroxyprogesterone  acetate  every  12  weeks  via 
intra-muscular  injection)  is  recommended  with  a 
close follow-up (every 12–24 weeks) of the endo-
metrium by hysteroscopy with biopsy or D & C and 
trans-vaginal  ultrasound  or  MRI  for  myometrial 
invasion.6,7,78
conclusion
According to this review, it seems that endometrial 
cancer  is  not  that  rare  in  women  aged  less  than 
40.  Hence,  we  can  conclude  that  a  conservative 
treatment for endometrial carcinoma at Stage IA with 
Table 1. Publications concerning medical treatment in endometrial adenocarcinoma and pregnancy outcome.
no of  
patients
Initial  
response
Recurrence progestogens  
(type and dose)
Fertility  
treatment
pregnancy Births
Farhi et al22 6 6 – MPA/Norethindrone None 1 1
Muechler et al79 1 1 – – Cc/hMG 1 0
Paulson et al80 1 1 0 Megestrol acetate IVF 2 1
Lai et al81 1 1 0 Megestrol acetate None 1 1
Randall &  
Kurman7
12 9 0 Megestrol acetate: 
40–160 mg/J
None 5 5
Kim et al6 21 13 3 Megestrol acetate: 
160 mg/J and others
None 6 6
Sardi et al12 4 3 0 MPA: 200–500 mg/J None – 3
Kaku et al10 12 9 2 MPA: 200–800 mg/J Cc 2 1
Imai et al14 14 8 3 MPA: 400–800 mg/J None – 3
Pinto et al82 1 1 0 Megestrol acetate IVF 1 1
Wang et al11 9 8 4 Various products None 3 3
Lowe et al13 2 2 0 Megestrol acetate: 
80 mg/J
– – 7
Gotlieb et al8 13 13 6 Megestrol acetate: 
160 mg/J or MPA: 
200–600 mg/J
– – 9
Jadoul &  
Donnez1
7 7 – Gn-RH agonists 6 IVF – 4
Niwa et al53 12 12 8 Medroxyprogesterone 
acetate  
400–600 mg/day
None 8 6
Ferrandina et al83 1 1 1 Dihydrogesterone  
20 mg/day
None 1 1
Ota et al4 12 6 3 MPA 600 mg/day None 4 2
Park et al84 1 1 0 Megestrol acetate 
600 mg/day
IVF 1 1
Wu et al85 1 1 1 Megestrol acetate 
160 mg/day
IVF 1 1
Yamazawa et al34 9 7 2 MPA 400 mg/day 3 IVF 4 3
Total 130 – – – – 58
Abbreviations: MPA, medroxyprogesterone acetate; Cc, Clomiphene citrate; hMG, human chorionic gonadotropins; IVF, in vitro fertilization.
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pre-therapeutic assessment is achieved and if a rig-
orous  follow-up  during  and  after  the  treatment  is 
pursued, achieving a complete response rate of 75%. 
A recurrence rate of 25% is seen after a temporary 
response.
However, no consensus has been drawn concerning 
the  ideal  treatment,  its  dose  or  its  duration,  even 
though medroxyprogesterone and megestrol acetate 
are the most used and the best explored. Furthermore, 
it  should  be  kept  in  mind  that  every  delay  in 
implementing radical treatment can increase the rate 
of recurrence or the development of metastasis, which 
will  systematically  worsen  the  prognosis.  Radical 
treatment should be indicated as soon as the desire to 
carry a pregnancy to term is fulfilled.
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